Inclusive of all taxes
Nitroglycerin Controlled Release Tablets 6.4 mg are specifically formulated for the management of cardiac conditions requiring sustained vasodilation and stable therapeutic plasma levels. These tablets provide a controlled release of nitroglycerin, ensuring consistent and prolonged cardiovascular effects. Manufactured under strict WHO-GMP guidelines, this controlled release formulation is designed to optimize angina pectoris treatment by minimizing the frequency of dosing and enhancing patient compliance. The formulation is export-grade, packaged in blister or strip packs suited for bulk distribution, and tested rigorously for dosage uniformity and safety. Ideal for hospitals, cardiac care centers, and pharmaceutical distributors targeting international markets, these tablets deliver dependable therapeutic performance with adherence to international pharmacopoeial standards (IP/USP).
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Nitroglycerin, 6.4 mg controlled release per tablet |
| Therapeutic Use | Management of cardiac conditions, particularly angina pectoris |
| Dosage Form | Controlled release oral tablets |
| Packaging | Export-grade blister or strip packs |
| Manufacturing Standards | Produced in WHO-GMP compliant facilities |
| Quality Compliance | Meets IP/USP pharmacopoeial standards |
| Shelf Life | As per regulatory standards, typically long shelf stability |
| Market Suitability | Compliant for international pharmaceutical export markets |
| Attributes | Description |
|---|---|
| Category | Cardiac Pharmaceutical |
| Formulation | Oral controlled release tablet |
| Strength | 6.4 mg nitroglycerin per tablet |
| Packaging Type | Blister or strip pack suitable for export |
| Shelf Life | Defined by regulatory authority, generally >2 years |
| Manufacturer | IndiGlobal Exports |
| Compliance | WHO-GMP, IP/USP standards |
| Intended Use | Clinical and hospital use for angina management |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The controlled release formulation provides a steady release of nitroglycerin which ensures consistent therapeutic effects over an extended period, reducing dosing frequency and improving patient adherence.
Yes, these tablets are manufactured in WHO-GMP compliant facilities and comply with IP/USP standards, making them suitable for regulated and semi-regulated international pharmaceutical markets.
The product is available in export-grade blister or strip packs designed for bulk export and institutional supply, ensuring product protection and compliance with export regulations.
The tablets are manufactured and supplied by IndiGlobal Exports, a reputed pharmaceutical exporter.
Absolutely, this formulation is widely prescribed in clinical and hospital settings to manage angina pectoris and other cardiac conditions requiring sustained nitroglycerin therapy.
Brand: indiglobal exports
Country Of Origin: India
Nitroglycerin Controlled Release Tablets 6.4 mg is a pharmaceutical product indicated for cardiac treatment. This formulation is manufactured with export-quality standards to ensure therapeutic efficacy, consistent dosage, and compliance with international healthcare regulations.
Features:Nitroglycerin Controlled Release Tablets 6.4 mg is developed for the effective management of cardiac conditions, offering reliable performance backed by stringent pharmaceutical standards. Each batch is carefully produced and tested to ensure consistency, safety, and compliance with global export norms.
This formulation supports the clinical treatment and ongoing care of patients with cardiac indications. Commonly prescribed in hospital and retail pharmacy settings, it ensures measurable therapeutic benefit.
Crafted in state-of-the-art facilities, this tablet formulation ensures accuracy in dosing and ease of administration. It is typically available in secure blister or strip packs suitable for bulk export or institutional supply.
The product is manufactured in facilities adhering to WHO-GMP standards and complies with pharmacopoeial quality benchmarks (IP/USP). Ideal for regulated and semi-regulated markets seeking quality-assured medications.
Inclusive of all taxes
You Save: 0
Panchkula , India
Service Provider , Professional Services, Exporter, Wholesaler
GST- 06eogps3248l1zf
